Skip to main content

Table 4 Cox regression analysis for risk of thromboembolic disease in lung adenocarcinoma

From: Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma

Variable

HR (95% CI)

Gender

 Male

1

 Female

0.83 (0.47–1.45)

Age

  < 66

1

  > 66

0.44 (0.23–0.82)

Stadium

 I

1

 II

3.10 (0.86–11.25)

 III

3.11 (0.94–10.32)

 IV

8.70 (2.90–26.17)

AC before the target event

 NO

1

 YES

1,10 (0.49–2.50)

Mutational status

 Non exposed

1

 EGFR+

0.46 (0.23–0.94)

 ALK+

0.61 (0.29–1.29)

  1. Significant covariates are shown. Adjusted for gender
  2. HR hazard ratio, 95% CI 95% confidence interval, NS not significant, AC anticoagulants, preventive dose for venous thromboembolism, EGFR+ patients bearing a mutation in the epidermal growth factor receptor (EGFR), ALK+ patients bearing a rearrangement of the anaplastic lymphoma kinase (ALK)